Ovarian

AstraZeneca Sued Over Cancer Drug Royalties

(The Telegraph [UK]) Feb 1, 2018 - Array BioPharma on Thursday sued AstraZeneca, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5bn (£6bn) collaboration with Merck & Co.

read article

Johnson and Johnson Falls On Report That Lawsuits Could Expose Potentially Damaging Documents

(CNBC) Feb 5, 2018 - J&J is facing numerous lawsuits claiming its talc products such as Johnson's Baby Powder caused cancer. The company has insisted its baby powder does not contain asbestos and causes neither mesothelioma nor ovarian cancer.

read article

Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed

(Morningstar) Feb 8, 2018 - Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, today announces the closure of its Phase 2a clinical trial (see NCT03042702) of Kevetrin for the treatment of late-stage Ovarian Cancer (OC).

read article

New Analysis Finds Patients Receiving Chemotherapy for Cancer at ADCC Institutions Have Highest Survival Rates

(Alliance of Dedicated Cancer Centers) Feb 6, 2018 - Patients treated with some of the most common types of cancer with chemotherapy at Dedicated Cancer Centers have higher survival rates compared to patients treated at other types of hospitals, according to new analysis conducted by Milliman for the Alliance of Dedicated Cancer Centers.

read press release

AstraZeneca Is Sued By Array Biopharma Over Cancer Drug Royalties

(Reuters) Feb 1, 2018 - Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

read article

Research Test Identifies BRCA2 Gene Mutations That Lead To Breast, Ovarian Cancers

(Mayo Clinic) Jan 25, 2018 - A new test developed by researchers at Mayo Clinic shows which mutations in the BRCA2 gene make women susceptible to developing breast or ovarian cancers.

read article

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

(StreetInsider) Jan 18, 2018 - Amgen and Allergan plc. today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab).

read article

PharmaMar Stock Crashes After Failed Ovarian Cancer Study

(Labiotech.eu) Jan 22, 2018 - PharmaMar’s cancer drug Zepsyre has failed to prove more effective than chemo to treat ovarian cancer in Phase III, leading to a big hit to its stock.

read article

Biosimilar Avastin Wins EU Approval

(PharmaTimes [UK]) Jan 22, 2018 - European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.

read article

Cancer 'Super Assassin': Huntington's Disease Molecule Can Target And Kill All Tumor Cells, Scientists Find

(Newsweek) Feb 12, 2018 - Scientists have destroyed numerous types of human cancer cells with a toxic molecule characteristic of fatal genetic illness Huntington’s disease.

read article

Ovarian Cancer Doesn’t Begin in the Ovaries, Researchers Say

(Wall Street Journal) Feb 12, 2018 - Ovarian cancer begins in the fallopian tubes, medical researchers say, suggesting new strategies to prevent and treat a lethal disease for which there isn’t good screening.

read article (paid subscription required)

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.

(New York Times) Feb 19, 2018 - Scientists are racing to understand why immunotherapy drugs have worked for a few cancer patients when the medicines should have had no effect.

read article

In Study, Stanford Researchers Analyze Ovarian Cancer Cells At Unprecedented Level Of Specificity

(Stanford Medicine/Scope Blog) Feb 20, 2018 - This Stanford Medicine study clarifies the underlying biology of high-grade serous ovarian cancer and could help lead to future therapies.

read article

Clovis Oncology Receives Positive Trend Vote From CHMP In European Regulatory Review For Rucaparib Ovarian Cancer Treatment Indication

(Clovis Oncology) Feb 21, 2018 - Clovis Oncology, Inc. announced today an update to the ongoing regulatory review for the Marketing Authorization Application (MAA) for rucaparib tablets as monotherapy for the treatment of a limited population of advanced ovarian cancer patients with deleterious BRCA mutation (germline and/or somatic).

read corporate press release

Ovarian Cancer Can Be Passed On Via Fathers - And It Strikes Younger

(The Telegraph [UK]) Feb 15, 2018 - Ovarian cancer can be passed on to women via their fathers, scientists have established for the first time.

read article

New Report: Labs Differ Widely In BRCA Testing Protocols

(Science Codex) Feb 15, 2018 - An international survey of genetic testing labs shows that - despite the availability of BRCA1 and BRCA2 testing for more than two decades - global protocols and standards are surprisingly inconsistent when it comes to analyzing cancer susceptibility genes and their many variations.

read article

Ovarian Cancer Screening Still Ineffective, Not Recommended: Panel

(U.S. News & World Report/HealthDay News) Feb 13, 2018 - Screening for ovarian cancer is not recommended for women with no signs or symptoms of the disease, newly released guidelines from the U.S. Preventive Services Task Force say.

read article

Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement

(The JAMA Network) Feb 13, 2018 - The USPSTF recommends against screening for ovarian cancer in asymptomatic women. (D recommendation) This recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome.

read article

Can Our Genes Help Predict How Women Respond To Ovarian Cancer Treatment?

(The Westmead Institute [Australia]) Feb 15, 2018 - New research has shown that the genes we inherit can have a significant impact on how the body processes chemotherapy drugs, which may lead to different clinical outcomes for ovarian cancer patients.

read article

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer

(AstraZeneca) Feb 23, 2018 - AstraZeneca and MSD’s new Lynparza tablet formulation recommended for maintenance therapy regardless of BRCA status.

read corporate press release
Next Page